With Gilead snapping at its heels in NASH, Intercept will be pleased with its product's positive reimbursement recommendation in the UK for rare disease PBC; physicians will have the opportunity to familiarize themselves with Intercept's offering.
NICE, the HTA body for England and Wales, has made a final appraisal determination recommending Intercept Pharmaceuticals Inc.'s FXR agonist Ocaliva (obeticholic acid) for routine use on the National Health Service (NHS) for the treatment of primary biliary cholangitis (PBC).
However, the company's key commercial success lays in securing approval for the product in non-alcoholic steatohepatitis (NASH), a much larger...
Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.
Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
